GO:0031694 alpha-2A adrenergic receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031694 (alpha-2A adrenergic receptor binding) is a molecular function defined as binding to an alpha-2A adrenergic receptor (ADRA2A).
• ADRA2A is a Gi/o-coupled receptor; ligand binding at this receptor inhibits adenylyl cyclase and modulates downstream signaling.
• The term is used to annotate proteins that physically interact with ADRA2A, including arrestin 3 and the amyloid precursor protein (APP).
• ADRA2A binding and signaling are relevant to neurodegeneration, amyloidogenesis, and methamphetamine responses in the hippocampus.
• Novel α2A agonists and partial agonists are being discovered through virtual screening and ensemble-based strategies.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of ADRA2A-binding proteins and receptor variants.
Description
GO:0031694, alpha-2A adrenergic receptor binding, is a molecular function term in the Gene Ontology that describes the binding of a protein or ligand to the alpha-2A adrenergic receptor (ADRA2A). ADRA2A is one of three alpha-2 adrenergic receptor subtypes and is a G protein-coupled receptor that couples primarily to Gi/o proteins, inhibiting adenylyl cyclase and reducing cAMP production. The receptor is widely expressed in the central nervous system and peripheral tissues, where it regulates neurotransmitter release, vascular tone, and metabolic processes. Researchers study this binding function to understand how endogenous catecholamines and synthetic ligands modulate ADRA2A activity and to identify proteins that scaffold or regulate the receptor. The alpha-2A adrenergic receptor binding function is not limited to classical agonists and antagonists. Intracellular proteins such as arrestin 3 and the amyloid precursor protein (APP) interact with ADRA2A and influence its endocytosis, trafficking, and signaling. These interactions have been linked to amyloidogenesis and Alzheimer's disease-related pathways, making GO:0031694 a relevant annotation for neurodegeneration research. Additionally, methamphetamine exposure has been shown to increase hippocampal ADRA2A and Gαo levels in mice, suggesting a role for this binding function in drug-induced plasticity. From a pharmacological perspective, alpha-2A adrenergic receptor binding is a target for drug discovery. Partial agonists and subtype-selective agonists have been developed to exploit therapeutic benefits while minimizing side effects. Recent studies have used virtual screening and ensemble-based strategies to identify novel scaffolds that bind ADRA2A and couple selectively to Gi/o proteins. The thyroid hormone metabolite 3-iodothyronamine also differentially modulates ADRA2A-mediated signaling, further highlighting the diversity of ligands that engage this binding function. Understanding the molecular details of GO:0031694 is therefore essential for both basic receptor biology and translational drug development.
alpha-2A adrenergic receptor binding At A Glance
| GO ID | GO:0031694 |
|---|---|
| GO term | alpha-2A adrenergic receptor binding |
| Ontology | molecular_function |
| Synonym | alpha-2A adrenergic receptor ligand |
| Definition | Binding to an alpha-2A adrenergic receptor. |
| Major function | Physical interaction with ADRA2A, enabling ligand-receptor binding and downstream Gi/o signaling. |
| Receptor family | Alpha-2 adrenergic receptor subtype; G protein-coupled receptor. |
| Primary coupling | Gi/o proteins, leading to inhibition of adenylyl cyclase. |
| Representative interactors | Arrestin 3, amyloid precursor protein (APP), Gαo. |
| Disease relevance | Neurodegeneration, amyloidogenesis, drug response. |
What Is GO:0031694?
GO:0031694 alpha-2A adrenergic receptor binding is defined by the Gene Ontology as the binding to an alpha-2A adrenergic receptor. In practice, this molecular function is annotated to any gene product that physically interacts with the alpha-2A adrenergic receptor (ADRA2A), whether it is an endogenous ligand, a synthetic agonist or antagonist, a scaffolding protein, or a regulatory protein such as arrestin. The synonym alpha-2A adrenergic receptor ligand reflects the fact that many annotated proteins act as ligands or ligand-like modulators of the receptor.
Why Is alpha-2A adrenergic receptor binding Important in Cell Biology?
GO:0031694 is important because alpha-2A adrenergic receptor binding is a central node in catecholamine signaling, and its dysregulation has been implicated in neurodegenerative and psychiatric conditions. The receptor is a validated drug target, and understanding which proteins bind ADRA2A and how binding alters receptor trafficking can guide the development of subtype-selective therapeutics. Moreover, the interaction between ADRA2A and APP disrupts APP-SorLA interaction and promotes amyloidogenesis, directly linking this binding function to Alzheimer's disease pathology. Thus, GO:0031694 provides a framework for annotating and studying proteins that modulate ADRA2A function in health and disease.
• ADRA2A binding regulates neurotransmitter release and vascular tone through Gi/o-mediated inhibition of adenylyl cyclase.
• The receptor is a target for antihypertensive, sedative, and analgesic drugs, making binding studies clinically relevant.
• APP binding to ADRA2A disrupts APP-SorLA interaction and promotes amyloidogenesis, linking GO:0031694 to Alzheimer's disease.
• Arrestin 3 recruitment to ADRA2A is modulated by APP, affecting receptor endocytosis and signaling.
• Methamphetamine increases hippocampal ADRA2A and Gαo levels, implicating this binding function in drug-induced neural plasticity.
• Novel α2A agonists identified by virtual screening show selective Gi/o coupling, offering new research tools.
• Partial agonists of ADRA2A reveal unique therapeutic benefits in heterozygous receptor mice.
• 3-iodothyronamine differentially modulates ADRA2A signaling, expanding the range of endogenous-like ligands.
• GO:0031694 annotations help identify proteins that scaffold or regulate GPCR function beyond classical pharmacology.
• CRISPR-based models enable causal testing of ADRA2A-binding proteins in disease-relevant cell types.
Molecular Mechanism of alpha-2A adrenergic receptor binding
Ligand recognition and binding pocket
In simple terms: The receptor has a pocket where natural hormones or drugs can dock.
The alpha-2A adrenergic receptor (ADRA2A) binds catecholamines and synthetic ligands through a conserved orthosteric pocket formed by transmembrane helices. Binding of agonists stabilizes an active receptor conformation that engages Gi/o proteins, while antagonists prevent this activation. Virtual screening and ensemble-based strategies have identified novel scaffolds that occupy this pocket and exhibit subtype selectivity. The binding event is the first step annotated by GO:0031694, and it determines whether downstream signaling proceeds.
G protein coupling and downstream signaling
In simple terms: Once a ligand binds, the receptor activates a G protein that turns down cAMP.
ADRA2A couples predominantly to Gi/o proteins, and agonist binding promotes GDP-GTP exchange on Gαi/o, leading to inhibition of adenylyl cyclase and reduced cAMP levels. This signaling cascade modulates neurotransmitter release and neuronal excitability. Novel α2A agonists that couple only to Gαi/o have been discovered, demonstrating that ligand bias can be engineered at this receptor. The binding function GO:0031694 is therefore directly linked to the efficacy of Gi/o-mediated signaling.
Regulation by arrestin and receptor trafficking
In simple terms: After activation, proteins like arrestin can bind the receptor and move it inside the cell.
Arrestin 3 recruitment to ADRA2A is a key regulatory step that promotes receptor endocytosis and desensitization. The amyloid precursor protein (APP) disrupts arrestin 3 recruitment to ADRA2A, thereby modulating receptor endocytosis and signaling. This interplay indicates that GO:0031694 encompasses not only agonist binding but also protein-protein interactions that control receptor fate. Dysregulation of these interactions can alter neuronal signaling and contribute to disease.
Modulation by endogenous and synthetic ligands
In simple terms: Different molecules can bind the receptor and change its activity in distinct ways.
The thyroid hormone metabolite 3-iodothyronamine differentially modulates ADRA2A-mediated signaling, showing that non-catecholamine ligands can engage this binding function. Partial agonists of ADRA2A produce unique therapeutic benefits in heterozygous receptor mice, highlighting the pharmacological relevance of graded binding responses. Methamphetamine exposure increases hippocampal ADRA2A and Gαo levels in mice, suggesting that drug-induced changes in receptor abundance can influence binding capacity. Together, these findings illustrate the diversity of ligands and conditions that regulate GO:0031694.
Pathological consequences of altered binding
In simple terms: When binding goes wrong, it can contribute to brain diseases like Alzheimer's.
ADRA2A binding to APP disrupts the APP-SorLA interaction and promotes amyloidogenesis, directly linking GO:0031694 to Alzheimer's disease pathology. This interaction shifts APP processing toward amyloidogenic pathways, and modulating ADRA2A binding may therefore influence amyloid plaque formation. The receptor's role in endocytosis and signaling further connects it to neuronal dysfunction. These findings position GO:0031694 as a molecular function with direct disease relevance.
Key Genes Involved in GO:0031694 alpha-2A adrenergic receptor binding
The following genes and proteins are experimentally linked to alpha-2A adrenergic receptor binding (GO:0031694) or its downstream biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADRA2A | Encodes the alpha-2A adrenergic receptor; primary binding target | Central to GO:0031694; target of agonists, antagonists, and partial agonists |
| ARRB2 | Arrestin 3 (beta-arrestin 2); binds activated ADRA2A | Regulates receptor endocytosis and desensitization; disrupted by APP |
| APP | Amyloid precursor protein; interacts with ADRA2A | Disrupts APP-SorLA interaction and promotes amyloidogenesis; modulates arrestin 3 recruitment |
| SORL1 | Sortilin-related receptor; interacts with APP | Its interaction with APP is disrupted by ADRA2A binding, affecting amyloidogenesis |
| GNAO1 | Gαo subunit; couples to ADRA2A | Mediates Gi/o signaling; increased in hippocampus after methamphetamine |
| GNAI1 | Gαi1 subunit; couples to ADRA2A | Participates in Gi/o-mediated inhibition of adenylyl cyclase |
| GNAI2 | Gαi2 subunit; couples to ADRA2A | Participates in Gi/o-mediated signaling |
| GNAI3 | Gαi3 subunit; couples to ADRA2A | Participates in Gi/o-mediated signaling |
| ADRA2B | Alpha-2B adrenergic receptor; related subtype | Used for comparative subtype selectivity studies |
| ADRA2C | Alpha-2C adrenergic receptor; related subtype | Used for comparative subtype selectivity studies |
| ADCY1 | Adenylyl cyclase 1; downstream effector | cAMP production is inhibited upon ADRA2A activation |
| ADCY2 | Adenylyl cyclase 2; downstream effector | cAMP production is inhibited upon ADRA2A activation |
| TH | Tyrosine hydroxylase; catecholamine synthesis | Provides endogenous ligands for ADRA2A binding |
| DBH | Dopamine beta-hydroxylase; norepinephrine synthesis | Provides endogenous ligands for ADRA2A binding |
| SLC6A2 | Norepinephrine transporter; regulates synaptic norepinephrine | Indirectly influences ligand availability for ADRA2A |
| COMT | Catechol-O-methyltransferase; catecholamine degradation | Regulates catecholamine levels available for receptor binding |
| MAOA | Monoamine oxidase A; catecholamine degradation | Regulates catecholamine levels available for receptor binding |
How Is alpha-2A adrenergic receptor binding Regulated?
The binding function GO:0031694 is regulated at multiple levels. Receptor abundance and availability are influenced by transcriptional control of ADRA2A and by methamphetamine exposure, which increases hippocampal ADRA2A and Gαo levels in mice. Agonist-induced desensitization and endocytosis are controlled by arrestin 3 recruitment, which can be disrupted by APP. Ligand availability is regulated by catecholamine synthesis (TH, DBH), reuptake (SLC6A2), and degradation (COMT, MAOA). Additionally, 3-iodothyronamine can differentially modulate ADRA2A-mediated signaling, indicating that endogenous metabolites can act as regulatory ligands. These layers of regulation ensure that alpha-2A adrenergic receptor binding is dynamically tuned to physiological and pharmacological contexts.
alpha-2A adrenergic receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADRA2A | Alzheimer's disease, amyloidogenesis | Knockout or point-mutation in neuronal cell lines; APP co-expression |
| APP | Alzheimer's disease, amyloidogenesis | Knock-in of APP mutations; ADRA2A binding assays |
| ARRB2 | Receptor endocytosis, neurodegeneration | Knockout of ARRB2; arrestin recruitment assays |
| GNAO1 | Methamphetamine response, neural plasticity | Overexpression of GNAO1 in hippocampal neurons |
| ADRA2A | Cardiovascular regulation, hypertension | Partial agonist treatment in heterozygous receptor mice |
Alzheimer's disease and amyloidogenesis
ADRA2A binding to APP disrupts the APP-SorLA interaction and promotes amyloidogenesis, a hallmark of Alzheimer's disease. This interaction shifts APP processing toward amyloidogenic pathways, and modulating ADRA2A binding may influence amyloid plaque formation. Additionally, APP modulates ADRA2A endocytosis and signaling by disrupting arrestin 3 recruitment, further linking GO:0031694 to neurodegeneration. These findings suggest that proteins annotated with alpha-2A adrenergic receptor binding are candidate therapeutic targets for Alzheimer's disease.
Substance use and methamphetamine response
Methamphetamine increases hippocampal alpha-2A adrenergic receptor and Gαo levels in mice, indicating that this binding function is responsive to drugs of abuse. The increase in receptor abundance may alter downstream Gi/o signaling and contribute to drug-induced neural plasticity. Understanding how methamphetamine regulates ADRA2A binding could inform strategies to mitigate substance use-related neural changes.
Cardiovascular and metabolic regulation
Alpha-2 adrenergic receptors, including ADRA2A, regulate vascular tone and neurotransmitter release, making them relevant to hypertension and metabolic control. Partial agonists of ADRA2A show unique therapeutic benefits in heterozygous receptor mice, suggesting that graded activation of this binding function can be exploited clinically. Thus, GO:0031694 is linked to cardiovascular and metabolic physiology through the receptor's role in catecholamine signaling.
From alpha-2A adrenergic receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ADRA2A binding to APP promote amyloidogenesis? | ADRA2A knockout or point-mutation in APP-expressing neuronal cells |
| How does APP disrupt arrestin 3 recruitment to ADRA2A? | ARRB2 knockout with ADRA2A overexpression |
| What is the effect of methamphetamine on ADRA2A and Gαo levels? | In vivo mouse model with hippocampal tissue analysis |
| Can partial agonists selectively activate ADRA2A? | Heterozygous ADRA2A receptor mice treated with partial agonists |
| Do novel agonists couple only to Gi/o? | ADRA2A knock-in cell lines with Gi/o-specific reporters |
| How does 3-iodothyronamine modulate ADRA2A signaling? | ADRA2A overexpression in heterologous cells |
How to Study the alpha-2A adrenergic receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity and kinetics of ligand-ADRA2A interaction | Characterizing novel agonists and antagonists |
| cAMP inhibition assay | Gi/o-mediated inhibition of adenylyl cyclase | Functional classification of ligands |
| BRET | G protein activation and receptor conformational changes | Detecting Gi/o coupling selectivity |
| Co-immunoprecipitation | Physical interaction between ADRA2A and proteins | Validating APP and arrestin 3 binding |
| FRET/PLA | Spatial and temporal protein-protein interactions | Monitoring arrestin recruitment in live cells |
| Virtual screening | Identification of novel chemical scaffolds | Discovery of α2A agonists |
| Mouse behavioral assays | Physiological and behavioral responses | Testing partial agonists and drug effects |
| Immunoblotting | Protein expression levels | Measuring ADRA2A and Gαo after methamphetamine |
Ligand binding assays
Radioligand binding assays using membrane preparations from cells expressing ADRA2A are standard for measuring affinity and kinetics of alpha-2A adrenergic receptor binding. These assays can be used to characterize novel agonists identified by virtual screening. Competition binding with subtype-selective compounds helps distinguish ADRA2A from ADRA2B and ADRA2C.
Cell-based signaling assays
cAMP inhibition assays and Gi/o activation measurements are used to assess functional consequences of ADRA2A binding. Bioluminescence resonance energy transfer (BRET) and GTPγS binding can monitor G protein coupling. These methods are essential for determining whether a ligand acts as a full agonist, partial agonist, or antagonist.
Protein-protein interaction studies
Co-immunoprecipitation and pull-down assays can detect interactions between ADRA2A and proteins such as APP and arrestin 3. Fluorescence resonance energy transfer (FRET) and proximity ligation assays provide spatial information about binding events in live cells. These techniques are critical for annotating proteins with GO:0031694.
In vivo and behavioral models
Mouse models, including heterozygous ADRA2A receptor mice, are used to study the physiological and behavioral effects of alpha-2A adrenergic receptor binding. Methamphetamine-treated mice provide a model for drug-induced changes in receptor and Gαo levels. Behavioral assays such as locomotor activity and memory tests can link binding function to whole-animal phenotypes.
How CRISPR Can Be Used to Study GO:0031694 alpha-2A adrenergic receptor binding
Knockout
CRISPR knockout of ADRA2A or its interacting partners (e.g., APP, ARRB2) can eliminate the binding function and reveal its role in downstream signaling and disease phenotypes. For example, ADRA2A knockout cells show altered APP processing and amyloidogenesis. Knockout of ARRB2 disrupts arrestin 3 recruitment and receptor endocytosis.
Point Mutation
Point mutations in ADRA2A can be introduced to dissect binding pocket residues or phosphorylation sites involved in arrestin recruitment. Such mutations help determine which amino acids are required for ligand binding and Gi/o coupling. Point mutations in APP can also be used to map the interaction interface with ADRA2A.
Knock-in
Knock-in of tagged ADRA2A (e.g., HA or GFP) enables visualization and purification of the receptor for binding studies. Knock-in of disease-associated APP mutations can model familial Alzheimer's disease and test how ADRA2A binding modulates amyloidogenesis. These models are valuable for studying GO:0031694 in a physiological context.
Overexpression
Overexpression of ADRA2A in heterologous cells is widely used for ligand binding and signaling assays. Overexpression of APP or arrestin 3 can enhance or disrupt ADRA2A binding and endocytosis. These systems allow researchers to study the molecular mechanism of alpha-2A adrenergic receptor binding in a controlled setting.
How EDITGENE Supports alpha-2A adrenergic receptor binding Research
Researchers studying alpha-2A adrenergic receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor function, signaling, or disease. EDITGENE provides CRISPR-based cell model services that enable precise genetic manipulation of ADRA2A and its interacting partners, helping you move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for alpha-2A adrenergic receptor binding research.
Frequently Asked Questions About alpha-2A adrenergic receptor binding
What is GO:0031694?
GO:0031694 is the Gene Ontology molecular function term for alpha-2A adrenergic receptor binding, defined as binding to an alpha-2A adrenergic receptor.
What is alpha-2A adrenergic receptor binding?
It is the physical interaction between a protein or ligand and the alpha-2A adrenergic receptor (ADRA2A), a Gi/o-coupled GPCR.
What genes are involved in alpha-2A adrenergic receptor binding?
Key genes include ADRA2A, ARRB2, APP, SORL1, GNAO1, GNAI1, GNAI2, and GNAI3.
How does ADRA2A binding affect Alzheimer's disease?
ADRA2A binding to APP disrupts APP-SorLA interaction and promotes amyloidogenesis, linking it to Alzheimer's pathology.
What proteins interact with ADRA2A?
Arrestin 3 (ARRB2), amyloid precursor protein (APP), and Gαo are known to interact with or be regulated by ADRA2A.
How can I study alpha-2A adrenergic receptor binding in the lab?
Common methods include radioligand binding, cAMP assays, BRET, co-immunoprecipitation, and CRISPR knockout models.
What are novel agonists of ADRA2A?
Recent studies have identified novel scaffold agonists and Gi/o-selective agonists through virtual screening and ensemble-based strategies.
Does methamphetamine affect ADRA2A?
Yes, methamphetamine increases hippocampal ADRA2A and Gαo levels in mice.
What is the role of arrestin 3 in ADRA2A binding?
Arrestin 3 is recruited to activated ADRA2A and regulates receptor endocytosis and signaling; APP can disrupt this recruitment.
Can CRISPR be used to study ADRA2A function?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal studies of ADRA2A and its interacting partners.
Conclusion
GO:0031694 alpha-2A adrenergic receptor binding is a molecular function that captures the diverse interactions between the alpha-2A adrenergic receptor and its ligands, scaffolding proteins, and regulatory partners. From Gi/o-mediated signaling to amyloidogenesis and drug responses, this binding function is central to neuronal and cardiovascular physiology. Continued research using CRISPR models and advanced binding assays will clarify how ADRA2A interactions contribute to disease and how they can be therapeutically modulated.
References
- 1. Sun S et al.. 2024. Novel Scaffold Agonists of the α(2A) Adrenergic Receptor Identified via Ensemble-Based Strategy.. Molecules 29(5) PMID: 38474611
- 2. Chen Y et al.. 2014. α(2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction.. Proc Natl Acad Sci U S A 111(48):17296-301 PMID: 25404298
- 3. Civantos Calzada B et al.. 2001. Alpha-adrenoceptor subtypes.. Pharmacol Res 44(3):195-208 PMID: 11529686
- 4. Zhou P et al.. 2024. The Discovery of Novel α(2a) Adrenergic Receptor Agonists Only Coupling to Gαi/O Proteins by Virtual Screening.. Int J Mol Sci 25(13) PMID: 39000340
- 5. Dinter J et al.. 2015. 3-iodothyronamine differentially modulates α-2A-adrenergic receptor-mediated signaling.. J Mol Endocrinol 54(3):205-16 PMID: 25878061
- 6. Tan CM et al.. 2002. Heterozygous alpha 2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists.. Proc Natl Acad Sci U S A 99(19):12471-6 PMID: 12205290
- 7. Zhang F et al.. 2017. The amyloid precursor protein modulates α(2A)-adrenergic receptor endocytosis and signaling through disrupting arrestin 3 recruitment.. FASEB J 31(10):4434-4446 PMID: 28646018
- 8. Nishio M et al.. 2002. Methamphetamine increases the hippocampal alpha(2A)-adrenergic receptor and Galpha(o) in mice.. Neurosci Lett 334(3):145-8 PMID: 12453616
